GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the US market in 2020 ... signaled it might walk back an earlier ruling that went ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

U.S. FDA calling for Zantac to be pulled from market immediately As the FDA’s investigation continued, they ultimately decided to issue an involuntary recall, pulling all prescription and over ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

"GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at 0754 GMT, misstated the day. About Dow Jones Newswires Dow Jones Newswires is a market-moving ... Learn More. Back To Top ...

Zantac was a blockbuster drug for GSK but was withdrawn from the U.S. market in 2020 after the FDA (Food and Drug Administration) requested its removal over concerns that it contained NDMA ...

GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly ... than market expectations of $3.5 billion, and the announcement came sooner than expected. The Zantac clouds ...

GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before litigation started in summer 2022. The drugs group rose 5% or 77.5p ...